EXECUTIVE ENGAGEMENTS
OUTREACH
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPETITORS
BRANDS
* Login for a full stack data experience
DATE
APR 2021
TABLES
165
PAGES
239
EDITION
8
PRICE
USD $4950
HIGHLIGHTS
SELECT PLAYERS
Caris Life Sciences; Genomic Health, Inc.; Helomics Corporation; HTG Molecular Diagnostics, Inc.; Illumina, Inc.; Nanostring Technologies, Inc.; NeoGenomics Laboratories, Inc.; Oxford Gene Technology; Qiagen NV; Ribomed Biotechnologies, Inc.
SEGMENTS
» Application (Clinical Application, Research Application) » Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancer Types) » Technology (Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry, Other Technologies (Pyrosequencing and Sanger Sequencing))
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
Influencer Market Insights |
World Market Trajectories |
Impact of Covid-19 and a Looming Global Recession |
Cancer/Tumor Profiling: Market Overview & Outlook |
Impact of Covid-19 and a Looming Global Recession |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
Increasing Incidence of Cancer Worldwide: Primary Growth Driver |
EXHIBIT: Cancer Rates (100,000 People) in Select Countries: 2021 |
EXHIBIT: Estimated New Cancer Cases & Deaths in the US by Sex: 2020 |
EXHIBIT: Estimated Number of New Cancer Cases in Men by Cancer Type: 2020 |
The United States: Characterized by Higher Incidence of Cancer |
EXHIBIT: Estimated New Cancer Cases & Deaths in the US by Sex: 2020 |
EXHIBIT: Estimated New Cases for Selected Cancers in the US by State: 2020 |
Enhanced Use of Biomarkers in Tumor Profiling Bodes Well |
Cancer Research & Funding Initiatives Augment Market Prospects |
Growing Role of Personalized Medicine Augurs Well |
Advances in Point-of-Care Cancer Diagnostics to Accelerate Uptake |
4. GLOBAL MARKET PERSPECTIVE |
World Current & Future Analysis for Cancer/Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Cancer/Tumor Profiling by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Cancer/Tumor Profiling by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Immunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Hybridization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Hybridization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Next Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Next Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Mass Spectrometry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Mass Spectrometry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Melanoma Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Melanoma Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Clinical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Clinical Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Clinical Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
World Current & Future Analysis for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
World Historic Review for Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
World 15-Year Perspective for Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027 |
III. MARKET ANALYSIS |
UNITED STATES |
USA Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
USA Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
USA Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
USA Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
USA 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
CANADA |
Canada Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
Canada Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
Canada Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Canada Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Canada 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
JAPAN |
Japan Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
Japan Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
Japan Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Japan Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Japan 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
CHINA |
China Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
China Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
China Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
China Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
China 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
EUROPE |
Europe Current & Future Analysis for Cancer/Tumor Profiling by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
Europe Historic Review for Cancer/Tumor Profiling by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Cancer/Tumor Profiling by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027 |
Europe Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
Europe Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
Europe Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Europe Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Europe 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
FRANCE |
France Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
France Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
France Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
France Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
France 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
GERMANY |
Germany Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
Germany Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
Germany Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Germany Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Germany 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
ITALY |
Italy Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
Italy Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
Italy Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Italy Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Italy 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
UNITED KINGDOM |
UK Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
UK Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
UK Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
UK Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
UK 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
REST OF EUROPE |
Rest of Europe Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
Rest of Europe Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
Rest of Europe Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of Europe Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of Europe 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
ASIA-PACIFIC |
Asia-Pacific Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
Asia-Pacific Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
Asia-Pacific Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Asia-Pacific Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Asia-Pacific 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
REST OF WORLD |
Rest of World Current & Future Analysis for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for Cancer/Tumor Profiling by Technology - Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of World 15-Year Perspective for Cancer/Tumor Profiling by Technology - Percentage Breakdown of Value Sales for Immunoassays, Hybridization, Next Generation Sequencing, Mass Spectrometry and Other Technologies for the Years 2012, 2020 & 2027 |
Rest of World Current & Future Analysis for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for Cancer/Tumor Profiling by Cancer Type - Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of World 15-Year Perspective for Cancer/Tumor Profiling by Cancer Type - Percentage Breakdown of Value Sales for Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer and Other Cancer Types for the Years 2012, 2020 & 2027 |
Rest of World Current & Future Analysis for Cancer/Tumor Profiling by Application - Clinical Application and Research Application - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
Rest of World Historic Review for Cancer/Tumor Profiling by Application - Clinical Application and Research Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR |
Rest of World 15-Year Perspective for Cancer/Tumor Profiling by Application - Percentage Breakdown of Value Sales for Clinical Application and Research Application for the Years 2012, 2020 & 2027 |
IV. COMPETITION |
Total Companies Profiled: 44 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com